<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two central issues in polyglutamine-induced <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> are the influence of the <z:mpath ids='MPATH_458'>normal</z:mpath> function of the disease protein and modulation by protein quality control pathways </plain></SENT>
<SENT sid="1" pm="."><plain>By using Drosophila, we now directly link host protein function and disease pathogenesis to ubiquitin pathways in the polyglutamine disease spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> human ataxin-3--a polyubiquitin binding protein with ubiquitin protease activity--is a striking suppressor of polyglutamine <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>This suppressor activity requires ubiquitin-associated activities of the protein and is dependent upon proteasome function </plain></SENT>
<SENT sid="4" pm="."><plain>Our results highlight the critical importance of host protein function in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> disease and a potential therapeutic role of ataxin-3 activity for polyglutamine disorders </plain></SENT>
</text></document>